Objectives: The purpose of this study was to evaluate the efficacy and safety of device
closure of patent foramen ovale (PFO) versus antiplatelet therapy in patients with …

Objectives: The present study was conducted to determine the safety of the transcatheter
closure of a patent foramen ovale (PFO) in patients with cryptogenic cerebral ischemia and …

ABSTRACT Background: Patent Foramen Ovale (PFO) occurs in approximately 25% of the
population and has been implicated in the etiology of cryptogenic stroke. Although the exact …

Objectives: The purpose of this study was to compare the efficacy of medical treatment with
percutaneous closure of patent foramen ovale (PFO). Background: Patients with cryptogenic …

Of cryptogenic stroke patients younger than 55 years of age, up to 61% have had a patent
foramen ovale (PFO). Observational studies have revealed reductions in recurrent …

Background: Percutaneous patent foramen ovale (PFO) closure seems to reduce the risk of
recurrent thromboembolism. We report the safety and efficacy of percutaneous PFO closure …

Objectives To examine long‐term clinical outcomes with transcatheter patent foramen ovale
(PFO) closure versus medical therapy alone in patients with cryptogenic stroke. Background …

Background Patent foramen ovale (PFO) closure is the gold standard for treating patients
with cryptogenic stroke and PFO. However, scarce data exist on the long-term outcomes …

Background The efficacy of closure of a patent foramen ovale (PFO) in the prevention of
recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO …

Background PFO is more common in cases with cryptogenic stroke compared to cases with
no stroke or stroke of identified etiology. Several randomized controlled trials (RCTs) …